REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

20/08/2025 09:26:01

lain Information	
Primary registry identifying number	Protocol number
LBCTR2019121368	CINC280A2201
MOH registration number	
ص/4331	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Retrospective	This study already started before LBCTR registry and still ongoing
Date of registration in national regulatory agency 15/05/2015	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharma Services Inc.
Date of registration in primary registry	Date of registration in national regulatory agency
16/05/2023	15/05/2015
Public title	Acronym
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer	
Scientific title	Acronym
A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)	
Brief summary of the study: English	
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.	
Brief summary of the study: Arabic	
ن الرئة غير ذي الخلايا الصغيرة INC280 الفموي cMET دراسة مرحلة ثانية متعددة المراكز لمنبّط المتقدّم من النوع الحاد EGFR	لدى المرضى البالغين المصابين بسرطان
Health conditions/problem studied: Specify	
advanced non-small cell lung cancer (NSCLC)	
Interventions: Specify	
INC280 (capmatinib)	
Key inclusion and exclusion criteria: Inclusion criteria	
Inclusion Criteria: •Stage IIIB or IV NSCLC (any histology) at the time of study entry	
•Histologically or cytologically confirmed diagnosis of NSCLC that is:	

 \sim

MINISTRY OF PUBLIC HEALTH


2 AND ALK-negative rearrangement as part of the patient standard of care by a validated test

1.EGFR wt as per patient standard of care by a validated test

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

3.AND (by central assessment) either: □Cohort 1: Pre-treated patients with cMET GCN \geq 6 or □Cohort 2: Pre-treated patients with cMET GCN ≥4 and < 6, or □Cohort 3: Pre-treated patients with cMET GCN < 4, or Cohort 4: Pre-treated patients with cMET mutations regardless of cMET GCN, or Cohort 5: Treatment-naïve patients with cMET dysregulation, or □Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET mutations or cMET mutations regardless of cMET GCN, or Cohort 7: Treatment-naïve patients with cMET mutations regardless of cMET GCN •To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease •To be eligible for Cohort 6, patients must have failed one prior line of systemic therapy for advanced/metastatic disease •To be eligible for Cohort 5 and Cohort 7, patients must not have received any systemic therapy for advanced/metastatic disease •At least one measurable lesion as defined by RECIST 1.1 Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study. •Patients must have adequate organ function •ECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion criteria may apply Key inclusion and exclusion criteria: Gender Key inclusion and exclusion criteria: Specify gender Both Key inclusion and exclusion criteria: Age minimum Key inclusion and exclusion criteria: Age maximum qq 18 Key inclusion and exclusion criteria: Exclusion criteria Exclusion Criteria: •Prior treatment with crizotinib, or any other cMET or HGF inhibitor •Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations •Patients with characterized ALK-positive rearrangement Clinically significant, uncontrolled heart diseases. •Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study. Strong inducers of CYP3A4 Impairment of GI function or GI disease that may significantly alter the absorption of INC280 •Patients receiving treatment with any enzyme-inducing anticonvulsant •Applicable to Cohorts 1-4 and Cohort 6 only: Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose •Pregnant or nursing women •Women of child-bearing potential, unless they are using highly effective methods of contraception •Sexually active males unless they use a condom during intercourse Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis Other protocol-defined exclusion criteria may apply Type of study Interventional Type of intervention Type of intervention: Specify type N/A Pharmaceutical Trial scope Trial scope: Specify scope N/A Therapy Study design: Allocation Study design: Masking N/A: Single arm study Open (masking not used) Study design: Control Study phase N/A 2 Study design: Purpose Study design: Specify purpose

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH	Lebanon Clinical Trials Registry
Treatment	N/A
Study design: Assignment Single	Study design: Specify assignment N/A
IMP has market authorization	IMP has market authorization: Specify
Νο	
Name of IMP	Year of authorization Month of authorization
INC280 (capmatinib)	
Type of IMP	
Others	
Pharmaceutical class	
adenosine triphosphate (ATP) competitive, reversible inhit	oitor of the c-MET receptor tyrosine kinase
Therapeutic indication Adult male and female patients with EGFR wt (for exon 19	
mutations), ALK-negative rearrangement, advanced (stage or two prior lines of systemic therapy for advanced/metast	e IIIB or IV) NSCLC who have received one atic disease.
Therapeutic benefit	
Overall Response Rate (ORR)	
Study model	Study model: Explain model
N/A	N/A
Study model: Specify model N/A	
Time perspective N/A	Time perspective: Explain time perspective N/A
Time perspective: Specify perspective N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description
Samples with DNA**	Samples shipped to central laboratory.
Target sample size	Actual enrollment target size
3	3



	REPUBLIC OF LEBANON Ministry of Public Health	Lebanon Clinical Trials Registry
--	--	----------------------------------

Date of first enrollment: Type Actual	Date of first enrollment: Date 20/04/2016
Date of study closure: Type Actual	Date of study closure: Date 02/03/2023
Recruitment status Complete	Recruitment status: Specify
Date of completion 12/02/2020	
IPD sharing statement plan	IPD sharing statement description
No	Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
	This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Additional data URL	
https://clinicaltrials.gov/ct2/show/record/NCT02414139?cond=Lung+Cancer	&cntry=LB&draw=2
Admin comments	
Trial status	
Approved	

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinical Trials .gov	NCT02414139	

Sources of Monetary or Material Support

Name

Novartis Pharma Services Inc

Secondary Sponsors Name

NA



Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Fadi Farhat	Saida	Lebanon	03-753155	drfadi.trials@gm ail.com	Hammoud Hospital University Medical Center
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1512002 # 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Joseph Kattan	Beirut	Lebanon	03-635913	jkattan62@hotm ail.com	Hotel Dieu De France
Public	Arafat Tfayli	Beirut	Lebanon	71-194294	Arafat.tfayli@aub .edu.lb	American University Of Beirut Medical Center

Centers/Hospitals Involved in the Study				
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval	
Hammoud Hospital University Medical Center	Fadi Farhat	Hematology- Oncology	Approved	
American University of Beirut Medical Center	Arafat Tfayli	Hematology- Oncology	Approved	
Hotel Dieu De France	Joseph Kattan	Hematology- Oncology	Approved	

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	14/09/2015	Fuad Ziyadeh	fz05@aub.edu.lb	961 (0) 1 350 000 ext:5445
Hotel Dieu de France	17/04/2015	Sami Richa	cue@usj.edu.lb	961421229
Hammoud Hospital University Medical Center	02/06/2017	Ahmad Zaatari	zaatari@hammoudhospital.com	961 (0) 7 723111 ext 1160



Countries of Recruitment
Name
Lebanon
Argentina
Austria
Brazil
Canada
China
France
Germany
Italy
Japan
Mexico
Netherlands
Norway
Turkey
United States of America

Health Conditions or Problems Studied		
Condition Code Keyword		
advanced non-small cell lung cancer (NSCLC)	Bronchus or lung, unspecified (C34.9)	advanced non-small cell lung cancer (NSCLC)

Interventions		
Intervention	Description	Keyword
Lab tests, ECG, Physical Exam , ICF	Lab tests, ECG, Physical Exam , ICF	Lab tests, ECG, Physical Exam , ICF





Primary Outcomes		
Name	Time Points	Measure
Overall Response Rate (ORR)	18 weeks	18 weeks

Key Secondary Outcomes		
Name	Time Points	Measure
Duration of Response (DOR)	18 weeks	18 weeks
Progression-free Survival	18 weeks	18 weeks

Trial Results

Summary results	
Study results globally	
Date of posting of results summaries	Date of first journal publication of results
Results URL link	
Baseline characteristics	
Participant flow	
Adverse events	
Outcome measures	
URL to protocol files	